Drug Profile
Basmisanil - Roche
Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; RG-1662; RO-5186582Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chromosome disorders; Down syndrome; Neurological disorders; Schizophrenia
Most Recent Events
- 04 Mar 2024 Discontinued - Phase-II for Chromosome disorders (In adolescents, In children) in USA, Portugal, Poland (PO) (NCT05307679)
- 04 Mar 2024 Roche terminates a phase II trial in Chromosome disorders (In adolescents, In children) in USA, Australia, Poland, Portugal, Spain and the UK (PO), due to slow recruitment (NCT05307679)
- 15 Feb 2024 Discontinued - Phase-II for Chromosome disorders (In adolescents, In children) in Australia, United Kingdom, Spain (PO) (Roche pipeline, February 2024)